Navigation Links
Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
Date:5/22/2012

BOSTON, May 22, 2012 /PRNewswire/ -- Rhythm announced today the results of a Phase 1b clinical trial of RM-131, the company's novel ghrelin agonist for the treatment of diabetic gastroparesis. The trial demonstrated that RM-131 greatly accelerates gastric emptying in patients with diabetic gastroparesis. The findings were presented at the Digestive Disease Week 2012 conference in San Diego.

The Phase 1b clinical trial was a randomized, double-blind, placebo-controlled, single-dose crossover study in 10 patients with type 2 diabetes, a history and symptoms of diabetic gastroparesis, and documentation of delayed gastric emptying. The primary objective of the study was to evaluate the pharmacodynamic profile of RM-131 administered as a single dose (100 mcg) to patients with diabetic gastroparesis. The trial also assessed safety and tolerability.

In the poster, "Randomized, Placebo-Controlled, Single-Dose, Crossover Study of the Effects of RM-131 in Type 2 Diabetics with Documented Delayed Gastric Emptying," Andrea Shin, M.D., a Mayo Clinic gastroenterology Fellow and study author, presented the following clinical data:

RM-131 is effective in accelerating gastric emptying in patients with type 2 diabetes and delayed gastric emptying.

Gastric emptying time was reduced by 66%.

The greatest improvement was observed in patients with the most abnormal gastric emptying.

RM-131 was generally well tolerated, with no serious adverse events

RM-131 was successfully designed to retain the pharmacodynamic properties of human ghrelin at lower and less frequent doses.


"We want to thank the Mayo Clinic for running this excellent clinical study," said Keith Gottesdiener, MD, CEO of Rhythm. "There is a great need for new treatments for diabetic gastroparesis, which afflicts patients with debilitating symptoms and causes frequent hospitalizations. These RM-131 results are encouraging and serve as the foundation for further clinical trials with RM-131 for the treatment of gastroparesis and other GI functional disorders."

About RM-131

RM-131 is a small-peptide analog of ghrelin, a hormone produced in the stomach that stimulates gastrointestinal activity. Derived from the natural ghrelin sequence, RM-131 has been optimized to stimulate gastrointestinal motility, with greater potency, and enhanced stability and pharmacokinetics.

About Gastroparesis

Gastroparesis affects a significant number of the 24 million diabetics in the U.S., with a prevalence of delayed gastric emptying of up to 30% among type 1 and type 2 diabetics. Gastroparesis symptoms include chronic nausea, vomiting, malnutrition, and results in a significant rate of hospitalization. This condition also often undermines measures to manage hyperglycemia.

About Rhythm (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and other GI functional disorders, and the MC4R peptide agonist, RM-493, for obesity and diabetes. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(857) 264-4281
bhenderson@rhythmtx.com <mailto:bhenderson@rhythmtx.com>

 


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
2. Guam rhino beetles got rhythm
3. Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions
4. Boston Scientific to Donate Cardiac Rhythm Management Devices to Heartbeat International for Implantation in Needy Patients
5. Biosense Webster Reinforces its Leadership Position in the Electrophysiology Market at Heart Rhythm 2010
6. Rhythms RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
7. Dangerous arrhythmia analyzed in a heartbeat
8. Differing structures underlie differing brain rhythms in healthy and ill
9. Rhythm Names Keith M. Gottesdiener Chief Executive Officer
10. Rhythm Names Lex Van der Ploeg Chief Scientific Officer
11. Rap music powers rhythmic action of medical sensor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... ... October 09, 2019 , ... ... Montgomery County middle school and high school students have improved neuro-cognitive executive skills ... techniques and physical fitness, and apply lifelong social/interpersonal, leadership, problem-solving and coping skills, ...
(Date:10/8/2019)... ... October 07, 2019 , ... Erchonia Corporation, the global ... today announces that the U.S. Food and Drug Administration (FDA) has granted the ... temporary relief of chronic neck and shoulder pain of musculoskeletal origin. , Erchonia ...
(Date:10/3/2019)... ... October 02, 2019 , ... Today marked the official ... enabling clinical program outsourcing success by cultivating radical improvements in leadership, staff, and ... executive Brenda Reese, phaseUP™ brings clients deep, broad and unique expertise in the ...
(Date:10/3/2019)... ... , ... Yesterday, at the 2019 meeting of Outsourcing in Clinical Trials New ... M.D., Ph.D., discussed important design factors that currently limit the success of early stage ... of clinical trials, in his talk Dr. Sherley focused on the highly ...
Breaking Biology Technology:
(Date:10/8/2019)... ... October 07, 2019 , ... Imaging data sets are generated ... optical projection tomography, optical coherence tomography, echocardiogram, light sheet microscopy, MRI and X-ray ... inhouse, a lot of research groups struggle with transforming these large and sometimes ...
(Date:10/4/2019)... ... 2019 , ... Representatives with MyBioGate ( https://events.mybiogate.com/ ) announced ... Hamburg Rothenbaumchaussee in Hamburg. , “To better connect Chinese companies and European markets, ... of Operations and spokesperson for MyBioGate. , Guo went on to highlight that ...
(Date:10/3/2019)... ... 01, 2019 , ... The CHEM+POUR Bag was ... and to be a more environmentally sustainable evolution to plastic or glass bottles. ... and feedback from the original version we launched in September 2015,” said Aaron ...
Breaking Biology News(10 mins):